Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 12;86(5):2812-2817.
doi: 10.1097/MS9.0000000000001939. eCollection 2024 May.

ST2 levels and neurodegenerative diseases: is this a significant relation?

Himanshu Arora  1 , Binish Javed  2 , L V Simhachalam Kutikuppala  3 , Mayuri Chaurasia  4 , Kaarvi Khullar  5 , Shreevikaa Kannan  6 , Varshitha Golla  7
Affiliations
Review

ST2 levels and neurodegenerative diseases: is this a significant relation?

Himanshu Arora et al. Ann Med Surg (Lond). .

Abstract

Interleukin-33 (IL-33), belonging to the interleukin-1 cytokine family, has a decoy receptor soluble ST2 (sST2). IL-33 is found in oligodendrocytes and astrocytes and is involved in central nervous system healing and repair, whereas ST2 is found in microglia and astrocytes. Some studies have found a link between changes in the IL-33/ST2 pathway and neurodegenerative disorders. This review article investigates the relationship between the interleukin-33 (IL-33)/ST2 pathway and neurodegenerative disorders. It was discovered that soluble st2 levels were increased. Furthermore, IL-33 levels were found to be lower in many neurodegenerative diseases such as Alzheimer's and amyotrophic lateral sclerosis (ALS). The association with other disorders, such as ankylosing spondylitis, multiple sclerosis, and systemic lupus erythematosus (SLE), was also observed. Various studies suggest that ST2/IL-33 signalling may be pivotal in the disease modulation of neurodegenerative disorders. The serum sST2 level test can be useful in determining the inflammatory status and severity of illness in many neurodegenerative disorders. In this review, we will discuss recent findings concerning the interleukin-33 (IL-33)/ST2 pathway and its role in the diagnosis and treatment of diseases with neurodegeneration.

Keywords: IL-33; central nervous system (CNS); neurodegenerative disorders; soluble ST2 levels.

PubMed Disclaimer

Conflict of interest statement

Not applicable.Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.

Figures

Figure 1
Figure 1
Mechanism underlying systemic lupus erythematosus.
Figure 2
Figure 2
Mechanism underlying Alzheimer’s disease.
See this image and copyright information in PMC

References

    1. Zheng C, Zhou XW, Wang JZ. The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ. Transl Neurodegener 2016;5:7. - PMC - PubMed
    1. Trajkovic V, Sweet MJ, Xu D. T1/ST2 - An IL-1 receptor-like modulator of immune responses. Cytokine Growth Factor Rev 2004;15(2–3):87–95. - PubMed
    1. Dinarello CA. An IL-1 family member requires caspase-1 processing and signals through the ST2 receptor. Immunity 2005;23:461–2. - PubMed
    1. Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol 2010;10:103–10. - PubMed
    1. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm 2011;8:1–12. - PMC - PubMed